SCHEMBL16748607

SCHEMBL16748607

N#CCc1nc2ccccc2n1-c1nc(N)nc(Nc2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 9/20 0.49
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PIK3CD O00329 4/20 0.41
PIK3CA P42336 4/20 0.41
PIK3CB P42338 4/20 0.41
MTOR P42345 4/20 0.41
PIK3CG P48736 4/20 0.41
MAPK1 P28482 1/20 0.39
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
KCNH3 Q9ULD8 1/20 0.36
DRD4 P21917 1/20 0.36
GRM2 Q14416 1/20 0.36
NOD1 Q9Y239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740876 0.89 BMI1 (0.52) BMI1CTSSCTSKPIK3CDPIK3CA
SCHEMBL16748621 0.88 BMI1 (0.51) BMI1SMN1; SMN2PIK3CDPIK3CAPIK3CB
SCHEMBL16740765 0.88 BMI1 (0.63) BMI1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL16740851 0.86 BMI1 (0.54) BMI1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL16748479 0.83 BMI1 (0.62) BMI1NPC1HTTRAB9APIK3CD
SCHEMBL16748513 0.82 BMI1 (0.50) BMI1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL16748612 0.80 BMI1 (0.40) BMI1NPC1HTTRAB9ASMN1; SMN2
SCHEMBL16740772 0.79 BMI1 (0.64) BMI1CTSSCTSKSMN1; SMN2PIK3CD
Hydrochloric Acid SCHEMBL16740736 0.78 BMI1 (0.63) BMI1CTSSCTSKSMN1; SMN2PIK3CD
SCHEMBL16740748 0.78 BMI1 (0.48) BMI1CTSKNPC1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885CTSS 4635/4885CTSK 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.